<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01917968</url>
  </required_header>
  <id_info>
    <org_study_id>U8090</org_study_id>
    <nct_id>NCT01917968</nct_id>
  </id_info>
  <brief_title>Uphold LITE Post-Market Surveillance Study</brief_title>
  <acronym>Uphold LITE</acronym>
  <official_title>A Prospective, Non-Randomized, Parallel Cohort, Multi-center Study of Uphold LITE Versus Native Tissue for the Treatment of Women With Anterior/Apical Pelvic Organ Prolapse</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Scientific Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare transvaginal mesh repair to traditional native tissue&#xD;
      repair in women surgically treated for anterior and/or apical pelvic organ prolapse.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective is to evaluate clinical effectiveness of transvaginal repair with mesh&#xD;
      (Uphold LITE) against traditional native tissue repair in women surgically treated for&#xD;
      anterior and/or apical pelvic organ prolapse. Secondary objectives are to evaluate Uphold&#xD;
      LITE-related complications and subject reported outcomes.&#xD;
&#xD;
      The primary endpoint of the study is to achieve superiority of transvaginal repair with mesh&#xD;
      (Uphold LITE) over native tissue repair at 36 months as compared to baseline. Success will be&#xD;
      based on a composite of objective and subjective measures.&#xD;
&#xD;
      Additionally, a co-primary endpoint of the study is to achieve non-inferiority of&#xD;
      transvaginal repair with mesh (Uphold LITE) to native tissue repair for safety by comparing&#xD;
      rates of serious device or serious procedure related complications between baseline and the&#xD;
      36 month time point.&#xD;
&#xD;
      The secondary endpoints of the study include assessments of complications and subject&#xD;
      reported outcomes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 10, 2013</start_date>
  <completion_date type="Actual">February 12, 2020</completion_date>
  <primary_completion_date type="Actual">February 12, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Efficacy Endpoint - Number of Participants With Composite Anatomic and Symptomatic Success at 36 Months</measure>
    <time_frame>36 Months</time_frame>
    <description>Success based on a composite of objective and subjective measures:&#xD;
Objective success was achieved by the subject having an anatomic outcome defined as the leading edge of prolapse at or above the hymen in the operated compartment:&#xD;
Anterior segment: Leading edge of anterior prolapse was at or above the hymen or POP-Q point Ba ≤ 0.&#xD;
Apical segment: The vaginal apex did not descend more than one-half into the vaginal canal (i.e., POP-Q point C &lt; -1/2 TVL) for multi-compartment prolapse or POP-Q point C ≤ 0 for single compartment apical prolapse.&#xD;
Subjective success was achieved if the patient denied symptoms of vaginal bulging per Pelvic Floor Distress Inventory (PFDI-20) question 3, answering &quot;no&quot; or &quot;yes&quot; but &quot;Not at all&quot; bothersome (&lt; 2).&#xD;
No retreatment for POP: no additional surgical treatment for POP in the segment(s) of the vagina treated at the index surgery or no pessary use since index surgery (i.e., 'treated segment' refers to the target compartment).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Co-Primary Safety Endpoint - Number of Participants With One or More Serious Device-Related and/or Procedure-Related Complications at 36 Months</measure>
    <time_frame>36 months</time_frame>
    <description>A co-primary endpoint of the study was to achieve non-inferiority of transvaginal repair with Uphold LITE vs. NTR for safety by comparing the overall complication rate (device-related and/or procedure-related SAEs) at 36 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary Endpoint - Number of Participants With Mesh Erosion and Exposures Over Time in Intent-to-Treat Subjects</measure>
    <time_frame>6 Month, 12 Months, 18 Months, 24 Months, 36 Months, Overall</time_frame>
    <description>Provides a summary of the number of subjects who reported mesh erosion or exposure at each of the study follow-up time points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Endpoint - Number of Participants With One or More Device-Related and/or Procedure-Related Adverse Events</measure>
    <time_frame>36 Months</time_frame>
    <description>Number of subjects with the following device-related and/or procedure-related adverse events: de novo dyspareunia, pelvic pain, infection, vaginal shortening, atypical vaginal discharge, neuromuscular problems, vaginal scarring, de novo vaginal bleeding, fistula formation, and/or de novo voiding dysfunction. The Intent-to-Treat (ITT) population includes all enrolled subjects who had a surgery initiated; the As Treated population includes all subjects who successfully completed the surgical procedure. Both ITT and As Treated populations are identical to the Overall Number of Participants Analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Endpoint - PFDI-20 Change From Baseline in Intent-to-Treat Subjects</measure>
    <time_frame>6 Month, 12 Months, 18 Months, 24 Months, 36 Months</time_frame>
    <description>The Pelvic Floor Distress Inventory-20 (PFDI-20) consists of three components: Pelvic Organ Prolapse Distress Inventory (POPDI; 6 questions), Urinary Distress Inventory (UDI; 6 questions), and Colorectal-Anal Distress Inventory (CRADI; 8 questions). Each individual component score is summed. The total ranges from 0 to 300, with a higher score indicating a greater impact to QOL (i.e., distress symptoms are more noticeable) and a lower score indicating a lesser impact to QOL (i.e., distress symptoms are less noticeable). Reported outcomes are the change from Baseline for the time periods indicated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Endpoint - PFIQ-7 Change From Baseline in Intent-to-Treat Subjects</measure>
    <time_frame>6 Month, 12 Months, 18 Months, 24 Months, 36 Months</time_frame>
    <description>The Pelvic Floor Impact Questionnaire (PFIQ-7) is composed of 3 separate but related assessments: the Urinary Impact Questionnaire, addresses the impact of urinary incontinence symptoms, the Colorectal-Anal Impact Questionnaire addresses the impact of colorectal-anal or bowel symptoms, and the Pelvic Organ Prolapse Impact Questionnaire addresses impact of vaginal and pelvic symptoms. For each question, the low score (0) corresponds to &quot;not at all&quot; and the high score (3) corresponds to &quot;quite a bit&quot;. The scores for the UIQ-7, CRAIQ-7 and POPIQ-7 are additive to yield the final PFIQ-7 score, which ranges from 0-300. A lower score means there is a lesser effect on quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Endpoint - PISQ-12 Change From Baseline in Intent-to-Treat Subjects</measure>
    <time_frame>6 Month, 12 Months, 18 Months, 24 Months, 36 Months</time_frame>
    <description>The Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire (PISQ-12) is a validated short form that can be used to ascertain improvement in sexual function and desire in women undergoing therapy for pelvic organ prolapse. The PISQ-12 consists of 12 questions graded on a five-point Likert scale ranging from 0 (always) to 4 (never). Values range from 0-48 and a higher score indicates better sexual function. Reported outcomes are the change from Baseline for the time periods indicated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Endpoint - TOMUS Pain Score Change From Baseline in Intent-to-Treat Subjects</measure>
    <time_frame>6 Month, 12 Months, 18 Months, 24 Months, 36 Months</time_frame>
    <description>The TOMUS Pain Score, a visual analog instrument with a scale of 0 (no pain sensation) to 10 (most intense pain sensation imaginable), was used to assess pain associated with surgery for pelvic organ prolapse. There are seven (7) questions each with a maximum score of 10 and a possible score range of 0-70. Reported outcomes are the change from Baseline for the time periods indicated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Endpoint: PGI-I for Prolapse Symptoms in Intent-to-Treat Subjects</measure>
    <time_frame>6 Month, 12 Months, 18 Months, 24 Months, 36 Months</time_frame>
    <description>The Patient Global Impression of Improvement (PGI-I) for prolapse symptoms is a validated QOL instrument that assesses patient perception of overall improvement after surgical interventions for pelvic organ prolapse. The scale is as follows: 1- Very much better; 2- Much better; 3- A little better; 4- No change; 5- A little worse; 6- Much worse; 7- Very much worse.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Endpoint - Number of Participants With Intervention for Recurrent Prolapse and Complications at 36 Months Post Index Procedure</measure>
    <time_frame>36 Months</time_frame>
    <description>Compares the office-based and surgical intervention for recurrent prolapse and complications between the Uphold LITE arm and the NTR arm 36 months from the index procedure in the Intent-to-Treat (ITT) and As Treated populations. The ITT population includes all enrolled subjects who had a surgery initiated; the As Treated population includes all subjects who successfully completed the surgical procedure. Both ITT and As Treated populations are identical to the Overall Number of Participants Analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Efficacy Endpoint - Number of Participants With Composite Anatomic and Symptomatic Success at 36 Months</measure>
    <time_frame>36 Months</time_frame>
    <description>Secondary efficacy endpoint defined similarly to the primary efficacy endpoint except for the definition of objective success. Objective success for this endpoint is defined as:&#xD;
Anatomic success in the operated compartment was achieved by:&#xD;
Anterior segment: No anterior prolapse at or beyond the hymen or POP-Q point Ba &lt; 0.&#xD;
Apical segment: The vaginal apex did not descend more than one-half into the vaginal canal (i.e., POP-Q point C &lt; -1/2 TVL) for multi-compartment prolapse or POP-Q point C &lt; 0 for single compartment apical prolapse.&#xD;
Subjective success was achieved if the patient denied symptoms of vaginal bulging per PFDI-20 question 3, answering &quot;no&quot; or &quot;yes&quot; but &quot;Not at all&quot; bothersome (&lt; 2).&#xD;
No retreatment for POP: No additional surgical treatment for POP in segment(s) of the vagina treated at the index surgery or no pessary use since index surgery ('treated segment' refers to the target compartments in this study, which are the anterior and apical compartments).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">289</enrollment>
  <condition>Pelvic Organ Prolapse</condition>
  <arm_group>
    <arm_group_label>Uphold Lightweight Vaginal Support System</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Transvaginal repair with mesh (Uphold LITE)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Traditional native tissue repair</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sacrospinous ligament fixation or uterosacral ligament suspension and/or colporrhaphy</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Uphold Lightweight Vaginal Support System</intervention_name>
    <description>Pelvic organ prolapse repair via transvaginal mesh (Uphold LITE)</description>
    <arm_group_label>Uphold Lightweight Vaginal Support System</arm_group_label>
    <other_name>Uphold LITE</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Traditional native tissue repair</intervention_name>
    <description>Sarcrospinous ligament fixation or uterosacral ligament suspension and/or colporrhaphy</description>
    <arm_group_label>Traditional native tissue repair</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject is female&#xD;
&#xD;
          2. Subject is ≥18 years of age&#xD;
&#xD;
          3. Subject has pelvic organ prolapse with the leading edge at or beyond the hymen. At or&#xD;
             beyond the hymen is defined as POP-Q scores of Ba≥0 or (for prolapse of the anterior&#xD;
             compartment alone) C≥0 (for prolapse of the apical compartment alone) or C≥-1/2 TVL&#xD;
             and Ba≥0 (for a multi-compartment prolapse that includes the anterior and apical&#xD;
             compartments).&#xD;
&#xD;
          4. Subject reports of a bothersome bulge they can see or feel per PFDI-20, question 3&#xD;
             response of 2 or higher (i.e. responses of &quot;somewhat&quot;, &quot;moderately&quot; or &quot;quite a bit&quot;)&#xD;
&#xD;
          5. Subject or subject's legally authorized representative must be willing to provide&#xD;
             written informed consent&#xD;
&#xD;
          6. Subject is willing and able to comply with the follow-up regimen&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subject has an active or chronic systemic infection including any gynecologic&#xD;
             infection, untreated urinary tract infection (UTI) or tissue necrosis&#xD;
&#xD;
          2. Subject has history of pelvic organ cancer (e.g. uterine, ovarian, bladder,&#xD;
             colo-rectal or cervical)&#xD;
&#xD;
          3. Subject has had prior or is currently undergoing radiation, laser therapy, or&#xD;
             chemotherapy in the pelvic area&#xD;
&#xD;
          4. Subject has taken systemic steroids (within the last month) or immunosuppressive or&#xD;
             immunomodulatory treatment (within the last 3 months)&#xD;
&#xD;
          5. Subject has systemic connective tissue disease (e.g. scleroderma, systemic lupus&#xD;
             erythematosus (SLE), Marfans syndrome, Ehlers Danlos, collagenosis, polymyositis&#xD;
             polymyalgia rheumatica)&#xD;
&#xD;
          6. Subject has a known neurologic or medical condition affecting bladder function (e.g.&#xD;
             multiple sclerosis, spinal cord injury, or stroke with residual neurologic deficit)&#xD;
&#xD;
          7. Subject is seeking obliterative vaginal surgery as treatment for pelvic organ prolapse&#xD;
             (colpocleisis)&#xD;
&#xD;
          8. Subject has a previous prolapse repair with mesh in the target compartment&#xD;
&#xD;
          9. Subject is planning to undergo a concomitant repair with use of mesh in the non-target&#xD;
             compartment&#xD;
&#xD;
         10. Subject is not able to conform to the modified dorsal lithotomy position&#xD;
&#xD;
         11. Subject has chronic systemic pain that includes the pelvic area or chronic focal pain&#xD;
             that includes the pelvis&#xD;
&#xD;
         12. Subject has uncontrolled diabetes mellitus (DM)&#xD;
&#xD;
         13. Subject is currently participating in or plans to participate in another device or&#xD;
             drug study during this study&#xD;
&#xD;
         14. Subject has a known hypersensitivity to polypropylene mesh&#xD;
&#xD;
         15. Subject is pregnant or intends to become pregnant during the study&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karen Noblett, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Irvine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham Kirklin Clinic</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montgomery Women's Health Associates, PC</name>
      <address>
        <city>Montgomery</city>
        <state>Alabama</state>
        <zip>36117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSD Health/Women's Pelvic Medicine Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sherry Thomas, PC</name>
      <address>
        <city>North Hollywood</city>
        <state>California</state>
        <zip>91301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of CA Irvine Medical Center</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente OB/GYN Urogynecology</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scripps Clinic Carmel Valley</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MedStar Washington Hospital Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Florida Bladder Institute</name>
      <address>
        <city>Naples</city>
        <state>Florida</state>
        <zip>34109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NorthShore University HealthSystem</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <zip>60201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Urology, LLC</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Capital Women's Care - Frederick</name>
      <address>
        <city>Frederick</city>
        <state>Maryland</state>
        <zip>21702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Las Vegas Minimally Invasive Surgery Women's Pelvic Health Center</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cooper University Hospital</name>
      <address>
        <city>Voorhees</city>
        <state>New Jersey</state>
        <zip>08043</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Irving Medical Center/NY Presbyterian Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Presbyterian Hospital</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lyndhurst Clinical Research</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Alexius Medical Center/Mid Dakota Clinic</name>
      <address>
        <city>Bismarck</city>
        <state>North Dakota</state>
        <zip>58501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati Physicians Co</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute for Female Pelvic Medicine &amp; Reconstructive Surgery</name>
      <address>
        <city>Allentown</city>
        <state>Pennsylvania</state>
        <zip>18103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute for Female Pelvic Medicine &amp; Reconstructive Surgery</name>
      <address>
        <city>North Wales</city>
        <state>Pennsylvania</state>
        <zip>19454</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prisma Health System</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Holston Medical Group at Seasons Center for Urogynecology &amp; Advanced Pelvic Surgery</name>
      <address>
        <city>Bristol</city>
        <state>Tennessee</state>
        <zip>37620</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. M. Mitchell Silver, FACOG, PA</name>
      <address>
        <city>Nacogdoches</city>
        <state>Texas</state>
        <zip>25965</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyle P. McMorries, MD</name>
      <address>
        <city>Nacogdoches</city>
        <state>Texas</state>
        <zip>75965</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Women's OB/GYN Center</name>
      <address>
        <city>Pasadena</city>
        <state>Texas</state>
        <zip>77505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MultiCare Women's Health Care</name>
      <address>
        <city>Covington</city>
        <state>Washington</state>
        <zip>98042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aurora West Allis Medical Center</name>
      <address>
        <city>West Allis</city>
        <state>Wisconsin</state>
        <zip>53227</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>July 18, 2013</study_first_submitted>
  <study_first_submitted_qc>August 5, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 7, 2013</study_first_posted>
  <results_first_submitted>February 12, 2021</results_first_submitted>
  <results_first_submitted_qc>February 17, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">March 15, 2021</results_first_posted>
  <last_update_submitted>April 29, 2021</last_update_submitted>
  <last_update_submitted_qc>April 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>POP</keyword>
  <keyword>Transvaginal</keyword>
  <keyword>Native Tissue Repair</keyword>
  <keyword>Repair Augmented with Mesh</keyword>
  <keyword>Pelvic Organ Prolapse</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prolapse</mesh_term>
    <mesh_term>Pelvic Organ Prolapse</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 28, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/68/NCT01917968/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>337 subjects were screened and 289 subjects were enrolled in the Uphold LITE Postmarket Surveillance Study. 225 subjects were enrolled in the Uphold LITE arm and 64 subjects in the NTR arm. 421 subjects from the AUGS PFD Registry (146 subjects from BSC's Xenform™ 522 study [NCT01945580], 69 subjects from Acell's MatriStem® 522 study, and 206 from Coloplast's 522 Restorelle® study) were pulled into the NTR arm for a total of 485 subjects in the NTR cohort and a total of 710 subjects overall.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Uphold Lightweight Vaginal Support System</title>
          <description>Transvaginal repair with mesh (Uphold LITE)&#xD;
Uphold Lightweight Vaginal Support System: Pelvic organ prolapse repair via transvaginal mesh (Uphold LITE)</description>
        </group>
        <group group_id="P2">
          <title>Traditional Native Tissue Repair</title>
          <description>Sacrospinous ligament fixation or uterosacral ligament suspension and/or colporrhaphy&#xD;
Traditional native tissue repair: Sarcrospinous ligament fixation or uterosacral ligament suspension and/or colporrhaphy</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="225"/>
                <participants group_id="P2" count="485"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="171"/>
                <participants group_id="P2" count="401"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="54"/>
                <participants group_id="P2" count="84"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="39"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="35"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject Relocation</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>36M Missed Visit</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject Noncompliance to Scheduled 36M Follow Up Visit</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Change in Family Circumstances</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>No Data Available</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Uphold Lightweight Vaginal Support System</title>
          <description>Transvaginal repair with mesh (Uphold LITE)&#xD;
Uphold Lightweight Vaginal Support System: Pelvic organ prolapse repair via transvaginal mesh (Uphold LITE)</description>
        </group>
        <group group_id="B2">
          <title>Traditional Native Tissue Repair</title>
          <description>Sacrospinous ligament fixation or uterosacral ligament suspension and/or colporrhaphy&#xD;
Traditional native tissue repair: Sarcrospinous ligament fixation or uterosacral ligament suspension and/or colporrhaphy</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="225"/>
            <count group_id="B2" value="485"/>
            <count group_id="B3" value="710"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66.1" spread="10.8"/>
                    <measurement group_id="B2" value="61.8" spread="10.5"/>
                    <measurement group_id="B3" value="63.2" spread="10.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="225"/>
                    <measurement group_id="B2" value="485"/>
                    <measurement group_id="B3" value="710"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="219"/>
                    <measurement group_id="B2" value="457"/>
                    <measurement group_id="B3" value="676"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="210"/>
                    <measurement group_id="B2" value="409"/>
                    <measurement group_id="B3" value="619"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not disclosed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="225"/>
                    <measurement group_id="B2" value="485"/>
                    <measurement group_id="B3" value="710"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Smoking</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Current</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Previous</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                    <measurement group_id="B2" value="139"/>
                    <measurement group_id="B3" value="198"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Never</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="147"/>
                    <measurement group_id="B2" value="308"/>
                    <measurement group_id="B3" value="455"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Recorded</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diabetes</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="63"/>
                    <measurement group_id="B3" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Menopausal Status</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Premenopausal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Perimenopausal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Postmenopausal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="209"/>
                    <measurement group_id="B2" value="404"/>
                    <measurement group_id="B3" value="613"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Previous Pelvic Surgery</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="169"/>
                    <measurement group_id="B2" value="235"/>
                    <measurement group_id="B3" value="404"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Primary Efficacy Endpoint - Number of Participants With Composite Anatomic and Symptomatic Success at 36 Months</title>
        <description>Success based on a composite of objective and subjective measures:&#xD;
Objective success was achieved by the subject having an anatomic outcome defined as the leading edge of prolapse at or above the hymen in the operated compartment:&#xD;
Anterior segment: Leading edge of anterior prolapse was at or above the hymen or POP-Q point Ba ≤ 0.&#xD;
Apical segment: The vaginal apex did not descend more than one-half into the vaginal canal (i.e., POP-Q point C &lt; -1/2 TVL) for multi-compartment prolapse or POP-Q point C ≤ 0 for single compartment apical prolapse.&#xD;
Subjective success was achieved if the patient denied symptoms of vaginal bulging per Pelvic Floor Distress Inventory (PFDI-20) question 3, answering &quot;no&quot; or &quot;yes&quot; but &quot;Not at all&quot; bothersome (&lt; 2).&#xD;
No retreatment for POP: no additional surgical treatment for POP in the segment(s) of the vagina treated at the index surgery or no pessary use since index surgery (i.e., 'treated segment' refers to the target compartment).</description>
        <time_frame>36 Months</time_frame>
        <population>337 subjects were screened and 289 subjects were enrolled in the Uphold LITE Postmarket Surveillance Study. 225 subjects were enrolled in the Uphold LITE arm and 64 subjects in the NTR arm. 421 subjects from the AUGS PFD Registry (146 subjects from BSC's Xenform™ 522 study [NCT01945580], 69 subjects from Acell's MatriStem® 522 study, and 206 from Coloplast's 522 Restorelle® study) were pulled into the NTR arm for a total of 485 subjects in the NTR cohort and a total of 710 subjects overall.</population>
        <group_list>
          <group group_id="O1">
            <title>Uphold Lightweight Vaginal Support System</title>
            <description>Transvaginal repair with mesh (Uphold LITE)&#xD;
Uphold Lightweight Vaginal Support System: Pelvic organ prolapse repair via transvaginal mesh (Uphold LITE)</description>
          </group>
          <group group_id="O2">
            <title>Traditional Native Tissue Repair</title>
            <description>Sacrospinous ligament fixation or uterosacral ligament suspension and/or colporrhaphy&#xD;
Traditional native tissue repair: Sarcrospinous ligament fixation or uterosacral ligament suspension and/or colporrhaphy</description>
          </group>
        </group_list>
        <measure>
          <title>Primary Efficacy Endpoint - Number of Participants With Composite Anatomic and Symptomatic Success at 36 Months</title>
          <description>Success based on a composite of objective and subjective measures:&#xD;
Objective success was achieved by the subject having an anatomic outcome defined as the leading edge of prolapse at or above the hymen in the operated compartment:&#xD;
Anterior segment: Leading edge of anterior prolapse was at or above the hymen or POP-Q point Ba ≤ 0.&#xD;
Apical segment: The vaginal apex did not descend more than one-half into the vaginal canal (i.e., POP-Q point C &lt; -1/2 TVL) for multi-compartment prolapse or POP-Q point C ≤ 0 for single compartment apical prolapse.&#xD;
Subjective success was achieved if the patient denied symptoms of vaginal bulging per Pelvic Floor Distress Inventory (PFDI-20) question 3, answering &quot;no&quot; or &quot;yes&quot; but &quot;Not at all&quot; bothersome (&lt; 2).&#xD;
No retreatment for POP: no additional surgical treatment for POP in the segment(s) of the vagina treated at the index surgery or no pessary use since index surgery (i.e., 'treated segment' refers to the target compartment).</description>
          <population>337 subjects were screened and 289 subjects were enrolled in the Uphold LITE Postmarket Surveillance Study. 225 subjects were enrolled in the Uphold LITE arm and 64 subjects in the NTR arm. 421 subjects from the AUGS PFD Registry (146 subjects from BSC's Xenform™ 522 study [NCT01945580], 69 subjects from Acell's MatriStem® 522 study, and 206 from Coloplast's 522 Restorelle® study) were pulled into the NTR arm for a total of 485 subjects in the NTR cohort and a total of 710 subjects overall.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="225"/>
                <count group_id="O2" value="485"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Intent to Treat Analysis</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="225"/>
                    <count group_id="O2" value="485"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="201"/>
                    <measurement group_id="O2" value="389"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Per Protocol</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="221"/>
                    <count group_id="O2" value="480"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="199"/>
                    <measurement group_id="O2" value="384"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.056</p_value>
            <p_value_desc>Statistical significance is considered at 0.05 level.</p_value_desc>
            <method>Z statistics</method>
            <method_desc>P-value is calculated using a Z statistics from the propensity score adjusted estimates. Missing values are handled using multiple imputation.</method_desc>
            <param_type>Adjusted difference in percentages</param_type>
            <param_value>6.5</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.2</ci_lower_limit>
            <ci_upper_limit>13.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Co-Primary Safety Endpoint - Number of Participants With One or More Serious Device-Related and/or Procedure-Related Complications at 36 Months</title>
        <description>A co-primary endpoint of the study was to achieve non-inferiority of transvaginal repair with Uphold LITE vs. NTR for safety by comparing the overall complication rate (device-related and/or procedure-related SAEs) at 36 months</description>
        <time_frame>36 months</time_frame>
        <population>337 subjects were screened and 289 subjects were enrolled in the Uphold LITE Postmarket Surveillance Study. 225 subjects were enrolled in the Uphold LITE arm and 64 subjects in the NTR arm. 421 subjects from the AUGS PFD Registry (146 subjects from BSC's Xenform™ 522 study [NCT01945580], 69 subjects from Acell's MatriStem® 522 study, and 206 from Coloplast's 522 Restorelle® study) were pulled into the NTR arm for a total of 485 subjects in the NTR cohort and a total of 710 subjects overall.</population>
        <group_list>
          <group group_id="O1">
            <title>Uphold Lightweight Vaginal Support System</title>
            <description>Transvaginal repair with mesh (Uphold LITE)&#xD;
Uphold Lightweight Vaginal Support System: Pelvic organ prolapse repair via transvaginal mesh (Uphold LITE)</description>
          </group>
          <group group_id="O2">
            <title>Traditional Native Tissue Repair</title>
            <description>Sacrospinous ligament fixation or uterosacral ligament suspension and/or colporrhaphy&#xD;
Traditional native tissue repair: Sacrospinous ligament fixation or uterosacral ligament suspension and/or colporrhaphy</description>
          </group>
        </group_list>
        <measure>
          <title>Co-Primary Safety Endpoint - Number of Participants With One or More Serious Device-Related and/or Procedure-Related Complications at 36 Months</title>
          <description>A co-primary endpoint of the study was to achieve non-inferiority of transvaginal repair with Uphold LITE vs. NTR for safety by comparing the overall complication rate (device-related and/or procedure-related SAEs) at 36 months</description>
          <population>337 subjects were screened and 289 subjects were enrolled in the Uphold LITE Postmarket Surveillance Study. 225 subjects were enrolled in the Uphold LITE arm and 64 subjects in the NTR arm. 421 subjects from the AUGS PFD Registry (146 subjects from BSC's Xenform™ 522 study [NCT01945580], 69 subjects from Acell's MatriStem® 522 study, and 206 from Coloplast's 522 Restorelle® study) were pulled into the NTR arm for a total of 485 subjects in the NTR cohort and a total of 710 subjects overall.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="225"/>
                <count group_id="O2" value="485"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Intent To Treat Analysis</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="225"/>
                    <count group_id="O2" value="485"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Per Protocol</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="221"/>
                    <count group_id="O2" value="480"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>With type I error of 0.05 and type II error of 0.20 (power 80%), 298 subjects (149 subjects per arm) are needed to detect non-inferiority with a margin of 10%.</non_inferiority_desc>
            <param_type>Adjusted difference in percentages</param_type>
            <param_value>-0.4</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.7</ci_lower_limit>
            <ci_upper_limit>1.9</ci_upper_limit>
            <estimate_desc>The propensity score adjusted difference in SAE rate of Uphold LITE transvaginal mesh (TVM) vs. NTR was estimated.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Secondary Endpoint - Number of Participants With Mesh Erosion and Exposures Over Time in Intent-to-Treat Subjects</title>
        <description>Provides a summary of the number of subjects who reported mesh erosion or exposure at each of the study follow-up time points.</description>
        <time_frame>6 Month, 12 Months, 18 Months, 24 Months, 36 Months, Overall</time_frame>
        <population>The population includes the 225 subjects in the Transvaginal repair with mesh (Uphold LITE) arm of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Total</title>
            <description>Inclusive</description>
          </group>
          <group group_id="O2">
            <title>Mild</title>
            <description>Measure of Severity</description>
          </group>
          <group group_id="O3">
            <title>Moderate</title>
            <description>Measure of Severity</description>
          </group>
          <group group_id="O4">
            <title>Severe</title>
            <description>Measure of Severity</description>
          </group>
        </group_list>
        <measure>
          <title>Secondary Endpoint - Number of Participants With Mesh Erosion and Exposures Over Time in Intent-to-Treat Subjects</title>
          <description>Provides a summary of the number of subjects who reported mesh erosion or exposure at each of the study follow-up time points.</description>
          <population>The population includes the 225 subjects in the Transvaginal repair with mesh (Uphold LITE) arm of the study.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="225"/>
                <count group_id="O2" value="225"/>
                <count group_id="O3" value="225"/>
                <count group_id="O4" value="225"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Erosion : Within 6 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erosion : Within 12 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erosion : Within 18 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erosion : Within 24 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erosion : Within 36 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erosion : Overall</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Exposure : Within 6 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Exposure : Within 12 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Exposure : Within 18 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Exposure : Within 24 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Exposure : Within 36 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Exposure : Overall</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Secondary Endpoint - Number of Participants With One or More Device-Related and/or Procedure-Related Adverse Events</title>
        <description>Number of subjects with the following device-related and/or procedure-related adverse events: de novo dyspareunia, pelvic pain, infection, vaginal shortening, atypical vaginal discharge, neuromuscular problems, vaginal scarring, de novo vaginal bleeding, fistula formation, and/or de novo voiding dysfunction. The Intent-to-Treat (ITT) population includes all enrolled subjects who had a surgery initiated; the As Treated population includes all subjects who successfully completed the surgical procedure. Both ITT and As Treated populations are identical to the Overall Number of Participants Analyzed.</description>
        <time_frame>36 Months</time_frame>
        <population>337 subjects were screened and 289 subjects were enrolled in the Uphold LITE Postmarket Surveillance Study. 225 subjects were enrolled in the Uphold LITE arm and 64 subjects in the NTR arm. 421 subjects from the AUGS PFD Registry (146 subjects from BSC's Xenform™ 522 study [NCT01945580], 69 subjects from Acell's MatriStem® 522 study, and 206 from Coloplast's 522 Restorelle® study) were pulled into the NTR arm for a total of 485 subjects in the NTR cohort and a total of 710 subjects overall.</population>
        <group_list>
          <group group_id="O1">
            <title>Uphold Lightweight Vaginal Support System</title>
            <description>Transvaginal repair with mesh (Uphold LITE)&#xD;
Uphold Lightweight Vaginal Support System: Pelvic organ prolapse repair via transvaginal mesh (Uphold LITE)</description>
          </group>
          <group group_id="O2">
            <title>Traditional Native Tissue Repair</title>
            <description>Sacrospinous ligament fixation or uterosacral ligament suspension and/or colporrhaphy&#xD;
Traditional native tissue repair: Sacrospinous ligament fixation or uterosacral ligament suspension and/or colporrhaphy</description>
          </group>
        </group_list>
        <measure>
          <title>Secondary Endpoint - Number of Participants With One or More Device-Related and/or Procedure-Related Adverse Events</title>
          <description>Number of subjects with the following device-related and/or procedure-related adverse events: de novo dyspareunia, pelvic pain, infection, vaginal shortening, atypical vaginal discharge, neuromuscular problems, vaginal scarring, de novo vaginal bleeding, fistula formation, and/or de novo voiding dysfunction. The Intent-to-Treat (ITT) population includes all enrolled subjects who had a surgery initiated; the As Treated population includes all subjects who successfully completed the surgical procedure. Both ITT and As Treated populations are identical to the Overall Number of Participants Analyzed.</description>
          <population>337 subjects were screened and 289 subjects were enrolled in the Uphold LITE Postmarket Surveillance Study. 225 subjects were enrolled in the Uphold LITE arm and 64 subjects in the NTR arm. 421 subjects from the AUGS PFD Registry (146 subjects from BSC's Xenform™ 522 study [NCT01945580], 69 subjects from Acell's MatriStem® 522 study, and 206 from Coloplast's 522 Restorelle® study) were pulled into the NTR arm for a total of 485 subjects in the NTR cohort and a total of 710 subjects overall.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="225"/>
                <count group_id="O2" value="485"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>De novo Dyspareunia : Intent-to-treat</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>De novo Dyspareunia : As treated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pelvic Pain : Intent-to-treat</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pelvic Pain : As treated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infection : Intent-to-treat</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infection : As treated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vaginal Shortening : Intent-to-treat</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vaginal Shortening : As treated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Atypical Vaginal Discharge : Intent-to-treat</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Atypical Vaginal Discharge : As treated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neuromuscular Problems : Intent-to-treat</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neuromuscular Problems : As treated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vaginal Scarring : Intent-to-treat</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vaginal Scarring : As treated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>De novo Vaginal Bleeding : Intent-to-treat</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>De novo Vaginal Bleeding : As treated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fistula Formation : Intent-to-treat</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fistula Formation : As treated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>De novo Voiding Dysfunction : Intent-to-treat</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>De novo Voiding Dysfunction : As treated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Secondary Endpoint - PFDI-20 Change From Baseline in Intent-to-Treat Subjects</title>
        <description>The Pelvic Floor Distress Inventory-20 (PFDI-20) consists of three components: Pelvic Organ Prolapse Distress Inventory (POPDI; 6 questions), Urinary Distress Inventory (UDI; 6 questions), and Colorectal-Anal Distress Inventory (CRADI; 8 questions). Each individual component score is summed. The total ranges from 0 to 300, with a higher score indicating a greater impact to QOL (i.e., distress symptoms are more noticeable) and a lower score indicating a lesser impact to QOL (i.e., distress symptoms are less noticeable). Reported outcomes are the change from Baseline for the time periods indicated.</description>
        <time_frame>6 Month, 12 Months, 18 Months, 24 Months, 36 Months</time_frame>
        <population>225 Uphold LITE arm subjects and 485 Native Tissue Repair arm subjects had available questionnaire data at Baseline. The number of participants at each follow up time point represents subjects who had available questionnaire data at Baseline and the time point indicated.</population>
        <group_list>
          <group group_id="O1">
            <title>Uphold LITE</title>
            <description>Transvaginal repair with mesh (Uphold LITE)&#xD;
Uphold Lightweight Vaginal Support System: Pelvic organ prolapse repair via transvaginal mesh (Uphold LITE)</description>
          </group>
          <group group_id="O2">
            <title>Native Tissue Repair</title>
            <description>Sacrospinous ligament fixation or uterosacral ligament suspension and/or colporrhaphy&#xD;
Traditional native tissue repair: Sacrospinous ligament fixation or uterosacral ligament suspension and/or colporrhaphy</description>
          </group>
        </group_list>
        <measure>
          <title>Secondary Endpoint - PFDI-20 Change From Baseline in Intent-to-Treat Subjects</title>
          <description>The Pelvic Floor Distress Inventory-20 (PFDI-20) consists of three components: Pelvic Organ Prolapse Distress Inventory (POPDI; 6 questions), Urinary Distress Inventory (UDI; 6 questions), and Colorectal-Anal Distress Inventory (CRADI; 8 questions). Each individual component score is summed. The total ranges from 0 to 300, with a higher score indicating a greater impact to QOL (i.e., distress symptoms are more noticeable) and a lower score indicating a lesser impact to QOL (i.e., distress symptoms are less noticeable). Reported outcomes are the change from Baseline for the time periods indicated.</description>
          <population>225 Uphold LITE arm subjects and 485 Native Tissue Repair arm subjects had available questionnaire data at Baseline. The number of participants at each follow up time point represents subjects who had available questionnaire data at Baseline and the time point indicated.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="225"/>
                <count group_id="O2" value="485"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>6 Months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="214"/>
                    <count group_id="O2" value="443"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-78.9" spread="57.3"/>
                    <measurement group_id="O2" value="-77.7" spread="53.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 Months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="203"/>
                    <count group_id="O2" value="442"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-74.8" spread="61.6"/>
                    <measurement group_id="O2" value="-76.9" spread="54.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18 Months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="184"/>
                    <count group_id="O2" value="415"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-78.5" spread="60.9"/>
                    <measurement group_id="O2" value="-77.3" spread="53.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 Months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="182"/>
                    <count group_id="O2" value="417"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-81.8" spread="56.6"/>
                    <measurement group_id="O2" value="-77.5" spread="53.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>36 Months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="170"/>
                    <count group_id="O2" value="400"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-73.5" spread="59.4"/>
                    <measurement group_id="O2" value="-77.2" spread="56.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Secondary Endpoint - PFIQ-7 Change From Baseline in Intent-to-Treat Subjects</title>
        <description>The Pelvic Floor Impact Questionnaire (PFIQ-7) is composed of 3 separate but related assessments: the Urinary Impact Questionnaire, addresses the impact of urinary incontinence symptoms, the Colorectal-Anal Impact Questionnaire addresses the impact of colorectal-anal or bowel symptoms, and the Pelvic Organ Prolapse Impact Questionnaire addresses impact of vaginal and pelvic symptoms. For each question, the low score (0) corresponds to &quot;not at all&quot; and the high score (3) corresponds to &quot;quite a bit&quot;. The scores for the UIQ-7, CRAIQ-7 and POPIQ-7 are additive to yield the final PFIQ-7 score, which ranges from 0-300. A lower score means there is a lesser effect on quality of life.</description>
        <time_frame>6 Month, 12 Months, 18 Months, 24 Months, 36 Months</time_frame>
        <population>222 Uphold LITE arm subjects and 485 Native Tissue Repair arm subjects had available questionnaire data at Baseline. The number of participants at each follow up time point represents subjects who had available questionnaire data at Baseline and the time point indicated.</population>
        <group_list>
          <group group_id="O1">
            <title>Uphold LITE</title>
            <description>Transvaginal repair with mesh (Uphold LITE)&#xD;
Uphold Lightweight Vaginal Support System: Pelvic organ prolapse repair via transvaginal mesh (Uphold LITE)</description>
          </group>
          <group group_id="O2">
            <title>Native Tissue Repair</title>
            <description>Sacrospinous ligament fixation or uterosacral ligament suspension and/or colporrhaphy&#xD;
Traditional native tissue repair: Sacrospinous ligament fixation or uterosacral ligament suspension and/or colporrhaphy</description>
          </group>
        </group_list>
        <measure>
          <title>Secondary Endpoint - PFIQ-7 Change From Baseline in Intent-to-Treat Subjects</title>
          <description>The Pelvic Floor Impact Questionnaire (PFIQ-7) is composed of 3 separate but related assessments: the Urinary Impact Questionnaire, addresses the impact of urinary incontinence symptoms, the Colorectal-Anal Impact Questionnaire addresses the impact of colorectal-anal or bowel symptoms, and the Pelvic Organ Prolapse Impact Questionnaire addresses impact of vaginal and pelvic symptoms. For each question, the low score (0) corresponds to &quot;not at all&quot; and the high score (3) corresponds to &quot;quite a bit&quot;. The scores for the UIQ-7, CRAIQ-7 and POPIQ-7 are additive to yield the final PFIQ-7 score, which ranges from 0-300. A lower score means there is a lesser effect on quality of life.</description>
          <population>222 Uphold LITE arm subjects and 485 Native Tissue Repair arm subjects had available questionnaire data at Baseline. The number of participants at each follow up time point represents subjects who had available questionnaire data at Baseline and the time point indicated.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="222"/>
                <count group_id="O2" value="485"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>6 Months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="212"/>
                    <count group_id="O2" value="443"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-51.2" spread="59.2"/>
                    <measurement group_id="O2" value="-41.0" spread="56.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 Months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="200"/>
                    <count group_id="O2" value="442"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-47.7" spread="66.6"/>
                    <measurement group_id="O2" value="-41.9" spread="55.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18 Months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="181"/>
                    <count group_id="O2" value="415"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-48.8" spread="66.4"/>
                    <measurement group_id="O2" value="-42.9" spread="58.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 Months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="179"/>
                    <count group_id="O2" value="417"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-50.3" spread="62.9"/>
                    <measurement group_id="O2" value="-41.5" spread="57.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>36 Months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="167"/>
                    <count group_id="O2" value="399"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-48.1" spread="62.9"/>
                    <measurement group_id="O2" value="-41.9" spread="55.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Secondary Endpoint - PISQ-12 Change From Baseline in Intent-to-Treat Subjects</title>
        <description>The Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire (PISQ-12) is a validated short form that can be used to ascertain improvement in sexual function and desire in women undergoing therapy for pelvic organ prolapse. The PISQ-12 consists of 12 questions graded on a five-point Likert scale ranging from 0 (always) to 4 (never). Values range from 0-48 and a higher score indicates better sexual function. Reported outcomes are the change from Baseline for the time periods indicated.</description>
        <time_frame>6 Month, 12 Months, 18 Months, 24 Months, 36 Months</time_frame>
        <population>90 Uphold LITE arm subjects and 234 Native Tissue Repair arm subjects had available questionnaire data at Baseline. The number of participants at each follow up time point represents those who had available questionnaire data at Baseline and the time point indicated.</population>
        <group_list>
          <group group_id="O1">
            <title>Uphold LITE</title>
            <description>Transvaginal repair with mesh (Uphold LITE)&#xD;
Uphold Lightweight Vaginal Support System: Pelvic organ prolapse repair via transvaginal mesh (Uphold LITE)</description>
          </group>
          <group group_id="O2">
            <title>Native Tissue Repair</title>
            <description>Sacrospinous ligament fixation or uterosacral ligament suspension and/or colporrhaphy&#xD;
Traditional native tissue repair: Sacrospinous ligament fixation or uterosacral ligament suspension and/or colporrhaphy</description>
          </group>
        </group_list>
        <measure>
          <title>Secondary Endpoint - PISQ-12 Change From Baseline in Intent-to-Treat Subjects</title>
          <description>The Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire (PISQ-12) is a validated short form that can be used to ascertain improvement in sexual function and desire in women undergoing therapy for pelvic organ prolapse. The PISQ-12 consists of 12 questions graded on a five-point Likert scale ranging from 0 (always) to 4 (never). Values range from 0-48 and a higher score indicates better sexual function. Reported outcomes are the change from Baseline for the time periods indicated.</description>
          <population>90 Uphold LITE arm subjects and 234 Native Tissue Repair arm subjects had available questionnaire data at Baseline. The number of participants at each follow up time point represents those who had available questionnaire data at Baseline and the time point indicated.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="234"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>6 Month</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="74"/>
                    <count group_id="O2" value="187"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4" spread="6.2"/>
                    <measurement group_id="O2" value="4.4" spread="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 Month</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="71"/>
                    <count group_id="O2" value="191"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9" spread="6.4"/>
                    <measurement group_id="O2" value="4.4" spread="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18 Month</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="62"/>
                    <count group_id="O2" value="172"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1" spread="5.7"/>
                    <measurement group_id="O2" value="4.0" spread="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 Month</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="173"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" spread="6.2"/>
                    <measurement group_id="O2" value="4.6" spread="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>36 Month</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="55"/>
                    <count group_id="O2" value="156"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2" spread="5.8"/>
                    <measurement group_id="O2" value="4.3" spread="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Secondary Endpoint - TOMUS Pain Score Change From Baseline in Intent-to-Treat Subjects</title>
        <description>The TOMUS Pain Score, a visual analog instrument with a scale of 0 (no pain sensation) to 10 (most intense pain sensation imaginable), was used to assess pain associated with surgery for pelvic organ prolapse. There are seven (7) questions each with a maximum score of 10 and a possible score range of 0-70. Reported outcomes are the change from Baseline for the time periods indicated.</description>
        <time_frame>6 Month, 12 Months, 18 Months, 24 Months, 36 Months</time_frame>
        <population>225 Uphold LITE arm subjects and 485 Native Tissue Repair arm subjects had available questionnaire data at Baseline. The number of participants at each follow up time point represents subjects who had available questionnaire data at Baseline and the time point indicated.</population>
        <group_list>
          <group group_id="O1">
            <title>Uphold LITE</title>
            <description>Transvaginal repair with mesh (Uphold LITE)&#xD;
Uphold Lightweight Vaginal Support System: Pelvic organ prolapse repair via transvaginal mesh (Uphold LITE)</description>
          </group>
          <group group_id="O2">
            <title>Native Tissue Repair</title>
            <description>Sacrospinous ligament fixation or uterosacral ligament suspension and/or colporrhaphy&#xD;
Traditional native tissue repair: Sacrospinous ligament fixation or uterosacral ligament suspension and/or colporrhaphy</description>
          </group>
        </group_list>
        <measure>
          <title>Secondary Endpoint - TOMUS Pain Score Change From Baseline in Intent-to-Treat Subjects</title>
          <description>The TOMUS Pain Score, a visual analog instrument with a scale of 0 (no pain sensation) to 10 (most intense pain sensation imaginable), was used to assess pain associated with surgery for pelvic organ prolapse. There are seven (7) questions each with a maximum score of 10 and a possible score range of 0-70. Reported outcomes are the change from Baseline for the time periods indicated.</description>
          <population>225 Uphold LITE arm subjects and 485 Native Tissue Repair arm subjects had available questionnaire data at Baseline. The number of participants at each follow up time point represents subjects who had available questionnaire data at Baseline and the time point indicated.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="225"/>
                <count group_id="O2" value="485"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>6 Months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="214"/>
                    <count group_id="O2" value="443"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.8" spread="8.1"/>
                    <measurement group_id="O2" value="-3.3" spread="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 Months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="203"/>
                    <count group_id="O2" value="442"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.4" spread="8.3"/>
                    <measurement group_id="O2" value="-3.8" spread="8.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18 Months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="184"/>
                    <count group_id="O2" value="415"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.5" spread="10.6"/>
                    <measurement group_id="O2" value="-4.2" spread="9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 Months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="182"/>
                    <count group_id="O2" value="417"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.6" spread="8.8"/>
                    <measurement group_id="O2" value="-3.9" spread="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>36 Months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="170"/>
                    <count group_id="O2" value="399"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.3" spread="8.7"/>
                    <measurement group_id="O2" value="-4.0" spread="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Secondary Endpoint: PGI-I for Prolapse Symptoms in Intent-to-Treat Subjects</title>
        <description>The Patient Global Impression of Improvement (PGI-I) for prolapse symptoms is a validated QOL instrument that assesses patient perception of overall improvement after surgical interventions for pelvic organ prolapse. The scale is as follows: 1- Very much better; 2- Much better; 3- A little better; 4- No change; 5- A little worse; 6- Much worse; 7- Very much worse.</description>
        <time_frame>6 Month, 12 Months, 18 Months, 24 Months, 36 Months</time_frame>
        <population>289 subjects were enrolled in the Uphold LITE study--225 in the Uphold LITE arm and 64 in the NTR arm. 421 subjects from AUGS PFD Registry (146 subjects from Xenform™ 522 study, 69 subjects from MatriStem® 522 study, and 206 from Restorelle® 522 study) were pulled into the NTR arm for a total of 485 subjects in the NTR cohort and a total of 710 subjects overall. The number of participants for each follow up time point represents subjects who had available questionnaire data at that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Uphold LITE</title>
            <description>Transvaginal repair with mesh (Uphold LITE)&#xD;
Uphold Lightweight Vaginal Support System: Pelvic organ prolapse repair via transvaginal mesh (Uphold LITE)</description>
          </group>
          <group group_id="O2">
            <title>Native Tissue Repair</title>
            <description>Sacrospinous ligament fixation or uterosacral ligament suspension and/or colporrhaphy&#xD;
Traditional native tissue repair: Sacrospinous ligament fixation or uterosacral ligament suspension and/or colporrhaphy</description>
          </group>
        </group_list>
        <measure>
          <title>Secondary Endpoint: PGI-I for Prolapse Symptoms in Intent-to-Treat Subjects</title>
          <description>The Patient Global Impression of Improvement (PGI-I) for prolapse symptoms is a validated QOL instrument that assesses patient perception of overall improvement after surgical interventions for pelvic organ prolapse. The scale is as follows: 1- Very much better; 2- Much better; 3- A little better; 4- No change; 5- A little worse; 6- Much worse; 7- Very much worse.</description>
          <population>289 subjects were enrolled in the Uphold LITE study--225 in the Uphold LITE arm and 64 in the NTR arm. 421 subjects from AUGS PFD Registry (146 subjects from Xenform™ 522 study, 69 subjects from MatriStem® 522 study, and 206 from Restorelle® 522 study) were pulled into the NTR arm for a total of 485 subjects in the NTR cohort and a total of 710 subjects overall. The number of participants for each follow up time point represents subjects who had available questionnaire data at that time point.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="225"/>
                <count group_id="O2" value="485"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>6 Month</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="214"/>
                    <count group_id="O2" value="441"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="0.7"/>
                    <measurement group_id="O2" value="1.3" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 Month</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="203"/>
                    <count group_id="O2" value="442"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="0.9"/>
                    <measurement group_id="O2" value="1.4" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18 Month</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="184"/>
                    <count group_id="O2" value="412"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="0.8"/>
                    <measurement group_id="O2" value="1.4" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 Month</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="182"/>
                    <count group_id="O2" value="417"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="0.9"/>
                    <measurement group_id="O2" value="1.4" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>36 Month</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="170"/>
                    <count group_id="O2" value="399"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" spread="1.0"/>
                    <measurement group_id="O2" value="1.4" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Secondary Endpoint - Number of Participants With Intervention for Recurrent Prolapse and Complications at 36 Months Post Index Procedure</title>
        <description>Compares the office-based and surgical intervention for recurrent prolapse and complications between the Uphold LITE arm and the NTR arm 36 months from the index procedure in the Intent-to-Treat (ITT) and As Treated populations. The ITT population includes all enrolled subjects who had a surgery initiated; the As Treated population includes all subjects who successfully completed the surgical procedure. Both ITT and As Treated populations are identical to the Overall Number of Participants Analyzed.</description>
        <time_frame>36 Months</time_frame>
        <population>337 subjects were screened and 289 subjects were enrolled in the Uphold LITE Postmarket Surveillance Study. 225 subjects were enrolled in the Uphold LITE arm and 64 subjects in the NTR arm. 421 subjects from the AUGS PFD Registry (146 subjects from BSC's Xenform™ 522 study [NCT01945580], 69 subjects from Acell's MatriStem® 522 study, and 206 from Coloplast's 522 Restorelle® study) were pulled into the NTR arm for a total of 485 subjects in the NTR cohort and a total of 710 subjects overall.</population>
        <group_list>
          <group group_id="O1">
            <title>Uphold LITE</title>
            <description>Transvaginal repair with mesh (Uphold LITE)&#xD;
Uphold Lightweight Vaginal Support System: Pelvic organ prolapse repair via transvaginal mesh (Uphold LITE)</description>
          </group>
          <group group_id="O2">
            <title>Native Tissue Repair</title>
            <description>Sacrospinous ligament fixation or uterosacral ligament suspension and/or colporrhaphy&#xD;
Traditional native tissue repair: Sacrospinous ligament fixation or uterosacral ligament suspension and/or colporrhaphy</description>
          </group>
        </group_list>
        <measure>
          <title>Secondary Endpoint - Number of Participants With Intervention for Recurrent Prolapse and Complications at 36 Months Post Index Procedure</title>
          <description>Compares the office-based and surgical intervention for recurrent prolapse and complications between the Uphold LITE arm and the NTR arm 36 months from the index procedure in the Intent-to-Treat (ITT) and As Treated populations. The ITT population includes all enrolled subjects who had a surgery initiated; the As Treated population includes all subjects who successfully completed the surgical procedure. Both ITT and As Treated populations are identical to the Overall Number of Participants Analyzed.</description>
          <population>337 subjects were screened and 289 subjects were enrolled in the Uphold LITE Postmarket Surveillance Study. 225 subjects were enrolled in the Uphold LITE arm and 64 subjects in the NTR arm. 421 subjects from the AUGS PFD Registry (146 subjects from BSC's Xenform™ 522 study [NCT01945580], 69 subjects from Acell's MatriStem® 522 study, and 206 from Coloplast's 522 Restorelle® study) were pulled into the NTR arm for a total of 485 subjects in the NTR cohort and a total of 710 subjects overall.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="225"/>
                <count group_id="O2" value="485"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Office-based Intervention for Recurrence : Intent-to-Treat</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Office-based Intervention for Recurrence : As Treated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Surgical Intervention for Recurrence : Intent-to-Treat</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Surgical Intervention for Recurrence : As Treated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Office-based Intervention for Complications : Intent-to-Treat</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Office-based Intervention for Complications : As Treated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Surgical Intervention for Complications : Intent-to-Treat</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Surgical Intervention for Complications : As Treated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Secondary Efficacy Endpoint - Number of Participants With Composite Anatomic and Symptomatic Success at 36 Months</title>
        <description>Secondary efficacy endpoint defined similarly to the primary efficacy endpoint except for the definition of objective success. Objective success for this endpoint is defined as:&#xD;
Anatomic success in the operated compartment was achieved by:&#xD;
Anterior segment: No anterior prolapse at or beyond the hymen or POP-Q point Ba &lt; 0.&#xD;
Apical segment: The vaginal apex did not descend more than one-half into the vaginal canal (i.e., POP-Q point C &lt; -1/2 TVL) for multi-compartment prolapse or POP-Q point C &lt; 0 for single compartment apical prolapse.&#xD;
Subjective success was achieved if the patient denied symptoms of vaginal bulging per PFDI-20 question 3, answering &quot;no&quot; or &quot;yes&quot; but &quot;Not at all&quot; bothersome (&lt; 2).&#xD;
No retreatment for POP: No additional surgical treatment for POP in segment(s) of the vagina treated at the index surgery or no pessary use since index surgery ('treated segment' refers to the target compartments in this study, which are the anterior and apical compartments).</description>
        <time_frame>36 Months</time_frame>
        <population>337 subjects were screened and 289 subjects were enrolled in the Uphold LITE Postmarket Surveillance Study. 225 subjects were enrolled in the Uphold LITE arm and 64 subjects in the NTR arm. 421 subjects from the AUGS PFD Registry (146 subjects from BSC's Xenform™ 522 study [NCT01945580], 69 subjects from Acell's MatriStem® 522 study, and 206 from Coloplast's 522 Restorelle® study) were pulled into the NTR arm for a total of 485 subjects in the NTR cohort and a total of 710 subjects overall.</population>
        <group_list>
          <group group_id="O1">
            <title>Uphold Lightweight Vaginal Support System</title>
            <description>Transvaginal repair with mesh (Uphold LITE)&#xD;
Uphold Lightweight Vaginal Support System: Pelvic organ prolapse repair via transvaginal mesh (Uphold LITE)</description>
          </group>
          <group group_id="O2">
            <title>Traditional Native Tissue Repair</title>
            <description>Sacrospinous ligament fixation or uterosacral ligament suspension and/or colporrhaphy&#xD;
Traditional native tissue repair: Sacrospinous ligament fixation or uterosacral ligament suspension and/or colporrhaphy</description>
          </group>
        </group_list>
        <measure>
          <title>Secondary Efficacy Endpoint - Number of Participants With Composite Anatomic and Symptomatic Success at 36 Months</title>
          <description>Secondary efficacy endpoint defined similarly to the primary efficacy endpoint except for the definition of objective success. Objective success for this endpoint is defined as:&#xD;
Anatomic success in the operated compartment was achieved by:&#xD;
Anterior segment: No anterior prolapse at or beyond the hymen or POP-Q point Ba &lt; 0.&#xD;
Apical segment: The vaginal apex did not descend more than one-half into the vaginal canal (i.e., POP-Q point C &lt; -1/2 TVL) for multi-compartment prolapse or POP-Q point C &lt; 0 for single compartment apical prolapse.&#xD;
Subjective success was achieved if the patient denied symptoms of vaginal bulging per PFDI-20 question 3, answering &quot;no&quot; or &quot;yes&quot; but &quot;Not at all&quot; bothersome (&lt; 2).&#xD;
No retreatment for POP: No additional surgical treatment for POP in segment(s) of the vagina treated at the index surgery or no pessary use since index surgery ('treated segment' refers to the target compartments in this study, which are the anterior and apical compartments).</description>
          <population>337 subjects were screened and 289 subjects were enrolled in the Uphold LITE Postmarket Surveillance Study. 225 subjects were enrolled in the Uphold LITE arm and 64 subjects in the NTR arm. 421 subjects from the AUGS PFD Registry (146 subjects from BSC's Xenform™ 522 study [NCT01945580], 69 subjects from Acell's MatriStem® 522 study, and 206 from Coloplast's 522 Restorelle® study) were pulled into the NTR arm for a total of 485 subjects in the NTR cohort and a total of 710 subjects overall.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="225"/>
                <count group_id="O2" value="485"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Intent to treat</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="225"/>
                    <count group_id="O2" value="485"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="188"/>
                    <measurement group_id="O2" value="353"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Per protocol</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="221"/>
                    <count group_id="O2" value="480"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="185"/>
                    <measurement group_id="O2" value="346"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>36 Months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Uphold Lightweight Vaginal Support System</title>
          <description>Transvaginal repair with mesh (Uphold LITE)&#xD;
Uphold Lightweight Vaginal Support System: Pelvic organ prolapse repair via transvaginal mesh (Uphold LITE)</description>
        </group>
        <group group_id="E2">
          <title>Traditional Native Tissue Repair</title>
          <description>Sacrospinous ligament fixation or uterosacral ligament suspension and/or colporrhaphy&#xD;
Traditional native tissue repair: Sarcrospinous ligament fixation or uterosacral ligament suspension and/or colporrhaphy</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="485"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac Event- New</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Cardiac Event- Worsening</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="485"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation - Worsening</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Ileus / Bowel Obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Other, Specify</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="485"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="225"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Infection- Other, Specify Type</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="485"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection - Other, specify type</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Pelvic Infection / Abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Pulmonary Event, Specify - NEW</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection (UTI), Lower</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="485"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ureteral Kink / Injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Visceral Organ Injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="485"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Other, Specify</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="485"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Mesh Exposure in Vagina</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="485"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hematoma - Retropubic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Mixed Incontinence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="485"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Pelvic Pain - NEW</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Prolapse</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="225"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="485"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary Event, Specify - Worsening</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="485"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Other, Specify</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="485"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Bleeding</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Bleeding Requiring Blood Transfusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Malignant Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Thrombotic Event</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="485"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="108" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="312" subjects_at_risk="485"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac Event - NEW</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Cardiac Worsening</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="485"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation - NEW</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="225"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Constipation - Worsening</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="225"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Fecal Incontinence - NEW</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" events="18" subjects_affected="18" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Fecal Incontinence - Worsening</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Hematoma - Retroperitoneal</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="225"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Hemorrhoids</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Ileus / Bowel Obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="225"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Neuromuscular Disorder, specify type</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Other, Specify</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="485"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Inflammation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Neuromuscular Disorder, specify type</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Other, Specify</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Pain, Other</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="225"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="485"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection - Other, specify type</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="225"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Other, Specify</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Pelvic Infection / Abscess</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="225"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Pulmonary Event, Specify - NEW</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection (UTI), Lower</sub_title>
                <counts group_id="E1" events="43" subjects_affected="31" subjects_at_risk="225"/>
                <counts group_id="E2" events="164" subjects_affected="118" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Vaginal Infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="225"/>
                <counts group_id="E2" events="18" subjects_affected="16" subjects_at_risk="485"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Other, Specify</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Visceral Organ Injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="485"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Buttock Pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="225"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Neuromuscular Disorder, specify type</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="225"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="485"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Neoplasia, Non-Pelvic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="485"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neuromuscular Disorder, specify type</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="225"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Neurovascular Event</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="485"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Mesh Exposure in Vagina</sub_title>
                <counts group_id="E1" events="12" subjects_affected="10" subjects_at_risk="225"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Suture Exposure in Vagina</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" events="20" subjects_affected="19" subjects_at_risk="485"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Difficulty Emptying Bladder - NEW</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="225"/>
                <counts group_id="E2" events="25" subjects_affected="24" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Difficulty Emptying Bladder - Worsening</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E2" events="7" subjects_affected="4" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Mixed Incontinence- Worsening</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Mixed Urinary Incontinence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Other, Specify</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Overactive Bladder</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="225"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Stress Incontinence - NEW</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="225"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Stress Incontinence - Worsening</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="225"/>
                <counts group_id="E2" events="21" subjects_affected="21" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Urge Incontinence - NEW</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="225"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Urge Incontinence - Worsening</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E2" events="26" subjects_affected="25" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Urinary Frequency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Urinary Urgency</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="225"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Weak Urinary Stream</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="485"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspareunia - NEW (De Novo)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="225"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Dyspareunia - Worsening</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Hematoma - Vaginal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Other, Specify</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="225"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Pelvic Pain - New</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="225"/>
                <counts group_id="E2" events="41" subjects_affected="39" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Pelvic Pain - Worsening</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Prolapse</sub_title>
                <counts group_id="E1" events="20" subjects_affected="20" subjects_at_risk="225"/>
                <counts group_id="E2" events="93" subjects_affected="88" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Sensation Of Bulge</sub_title>
                <counts group_id="E1" events="27" subjects_affected="26" subjects_at_risk="225"/>
                <counts group_id="E2" events="55" subjects_affected="53" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Sensation Of Pressure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Vaginal Atrophy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Vaginal Bleeding, De Novo</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Vaginal Discharge, Atypical</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="225"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Vaginal Scarring</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Vaginal Shortening</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Vaginal Wall Dehiscence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Vulvar Itching</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Vulvar Lesion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="485"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Other, Specify</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="485"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Lichen Sclerosus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Skin Condition</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Tissue Granulation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="225"/>
                <counts group_id="E2" events="33" subjects_affected="33" subjects_at_risk="485"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Bleeding</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Hematoma - Other</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Other, Specify</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="485"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Before publishing, Institution and Investigator shall submit copies of any proposed publication or presentation to Sponsor for review at least sixty (60) days in advance of submission for publication or presentation to a publisher or other third party. Sponsor reserves the right to delete any Confidential Information or other proprietary information of Sponsor (including trade secrets but not including Results) from the proposed publication or presentation.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Director, Clinical Operations</name_or_title>
      <organization>Boston Scientific Corporation</organization>
      <phone>952-930-6000</phone>
      <email>teresa.takle-flach@bsci.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

